Eli Lilly's retatrutide delivered 28.3% average weight loss in Phase 3 and 30.3% in severe obesity patients at two years, matching bariatric surgery outcomes. Here is what the TRIUMPH-1 results mean for the obesity drug market.

Key Highlights

  • Participants on the highest 12 mg dose lost an average of 28.3% of body weight over 80 weeks in the TRIUMPH-1 trial
  • Patients with severe obesity who continued to 104 weeks lost an average of 30.3%, matching outcomes typical of gastric bypass surgery
  • The drug targets three gut hormones simultaneously, making it more potent than any currently approved obesity therapy
  • At the lowest 4 mg dose, fewer patients stopped treatment due to side effects than in the placebo group
  • Eli Lilly is expected to seek regulatory approval following the results, with a potential launch in 2027

What Happened

Eli Lilly (NYSE: LLY) announced Phase 3 trial results for retatrutide on Thursday, and the numbers were striking.

In the TRIUMPH-1 trial involving 2,399 participants, those on the highest 12 mg weekly dose lost an average of 70.3 pounds, or 28.3% of their body weight, over 80 weeks. Those on the placebo lost just 2.2%.

The results went further in a longer extension of the study. Patients with a body mass index of 35 or above who continued to 104 weeks lost an average of 85 pounds, or 30.3% of their body weight. That level of weight loss has historically only been achieved through bariatric surgery, which typically delivers 30% to 35% reduction over two years.

For comparison, Lilly's own Zepbound, currently one of the most effective approved obesity drugs on the market, delivers around 20% to 22% weight loss at its highest dose.

How the Drug Works

Retatrutide belongs to a class of drugs called incretin mimetics, which mimic gut hormones to reduce appetite, slow digestion, and improve blood sugar control.

What sets it apart is how many hormones it targets. Novo Nordisk (NYSE:NVO) semaglutide, the active ingredient in Wegovy and Ozempic, targets one hormone: GLP1. Eli Lilly's tirzepatide, sold as Zepbound and Mounjaro, targets two: GLP-1 and GIP. Retatrutide targets all three, adding glucagon, a hormone linked to energy expenditure that the other drugs do not engage.

Researchers are not entirely certain why hitting three receptors produces such a large additional benefit. The clinical outcomes, however, are clear.

Among participants on the highest dose, 62.5% lost more than 25% of their body weight, 45.3% lost more than 30%, and 27.2% lost more than 35%. In tirzepatide's own Phase 3 trial, 36.2% of patients on the highest dose lost more than 25%.

The Low-Dose Finding

One result from TRIUMPH-1 that drew particular attention was the performance of the 4 mg dose, a level not tested in any previous retatrutide trial.

Participants at this dose lost an average of 47.2 pounds, or 19% of body weight, over 80 weeks. That is roughly comparable to what Zepbound achieves at its highest approved dose.

What stood out was the tolerability. Only about 4% of patients on the 4 mg dose stopped treatment because of side effects, compared with nearly 5% in the placebo group. That is an unusual outcome for this class of drug, where gastrointestinal side effects frequently push dropout rates above placebo levels.

Lilly's chief scientific officer Dan Skovronsky described it as remarkable, noting that not every patient needs or wants the maximum dose. For some, a lower dose with comparable efficacy to existing market leaders and better tolerability may be the more practical option.

Side Effects at the Highest Dose

The highest dose carried a more demanding tolerability profile. Around 42% of patients reported nausea, 32% reported diarrhoea, and 26% reported constipation. More than 12% experienced dysesthesia, an abnormal skin or nerve sensation flagged in earlier trials, though the rate was lower than in prior studies.

Around 11.3% of patients on the highest dose discontinued treatment due to side effects, a higher rate than seen with tirzepatide. Lilly also noted a slightly elevated rate of urinary tract infections at 8%, which the company suggested may be related to the pace of weight loss rather than the drug itself, as a similar pattern is observed following bariatric surgery.

Importantly, Lilly reported no cardiac or liver complications, addressing a concern some analysts had raised given the drug's activation of the glucagon receptor.

What This Means for the Market

Lilly currently holds approximately 60% of the combined United States obesity and diabetes drug market, against Novo Nordisk's 39%. Retatrutide strengthens that position considerably, assuming regulatory approval.

Novo is developing a competing triple agonist following a deal worth up to $2 billion struck in early 2025 with United Laboratories International, a Chinese pharmaceutical firm. That drug, however, remains in early-stage development and is several years away from late-stage trials.

Lilly has not yet filed for regulatory approval with the Food and Drug Administration (FDA). That filing is expected to follow the TRIUMPH-1 data, with a potential market launch in 2027. A separate legal dispute with the FDA over whether retatrutide should be classified as a conventional drug or a biologic remains unresolved. Biologic status would give Lilly longer market exclusivity and greater pricing power.

Analysts have estimated retatrutide could generate $3.8 billion in sales by 2030. Some projections place the broader GLP-1 drug market at close to $100 billion annually by the early 2030s.

With no rival triple agonist close to approval and its existing portfolio already dominant, Lilly enters the regulatory stretch for retatrutide in the strongest competitive position it has held since the obesity drug era began.